These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 2828443)

  • 1. Prospects for vaccines for herpes simplex viruses.
    Berman PW
    J Am Acad Dermatol; 1988 Jan; 18(1 Pt 2):226-30. PubMed ID: 2828443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Yeast-derived glycoprotein B-1 of herpes simplex virus (HSV) as a candidate for an HSV vaccine.
    Kino Y
    Adv Exp Med Biol; 1990; 278():183-90. PubMed ID: 1963033
    [No Abstract]   [Full Text] [Related]  

  • 3. Protective immunization of mice with specific HSV-1 glycoproteins.
    Chan WL
    Immunology; 1983 Jun; 49(2):343-52. PubMed ID: 6303950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens.
    Awasthi S; Mahairas GG; Shaw CE; Huang ML; Koelle DM; Posavad C; Corey L; Friedman HM
    J Virol; 2015 Aug; 89(16):8497-509. PubMed ID: 26041292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preinfection prophylaxis with herpes simplex virus glycoprotein immunogens: factors influencing efficacy.
    Stanberry LR; Myers MG; Stephanopoulos DE; Burke RL
    J Gen Virol; 1989 Dec; 70 ( Pt 12)():3177-85. PubMed ID: 2558156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Herpes simplex virus vaccines.
    Meignier B; Roizman B
    Antiviral Res; 1985; Suppl 1():259-65. PubMed ID: 3002260
    [No Abstract]   [Full Text] [Related]  

  • 8. Recombinant interleukin 2 as an adjuvant for vaccine-induced protection. Immunization of guinea pigs with herpes simplex virus subunit vaccines.
    Weinberg A; Merigan TC
    J Immunol; 1988 Jan; 140(1):294-9. PubMed ID: 2826591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenic properties of formalin herpes antigen prepared from cell cultures.
    Benda R; Dbalý V
    J Hyg Epidemiol Microbiol Immunol; 1973; 17(2):237-49. PubMed ID: 4354219
    [No Abstract]   [Full Text] [Related]  

  • 10. Humoral and cellular immune responses to an envelope-associated antigen of herpes simplex virus.
    Zaia JA; Palmer EL; Feorino PM
    J Infect Dis; 1975 Dec; 132(6):660-6. PubMed ID: 172562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes.
    Stanberry LR; Bernstein DI; Burke RL; Pachl C; Myers MG
    J Infect Dis; 1987 May; 155(5):914-20. PubMed ID: 3031173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a herpes simplex virus subunit glycoprotein vaccine for prophylactic and therapeutic use.
    Burke RL
    Rev Infect Dis; 1991; 13 Suppl 11():S906-11. PubMed ID: 1664126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation and efficacy of an inactivated subunit vaccine (NFUIBHK) against type 2 Herpes simplex virus infection.
    Skinner GR; Williams DR; Buchan A; Whitney J; Harding M; Bodfish K
    Med Microbiol Immunol; 1978 Nov; 166(1-4):119-32. PubMed ID: 214676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D prevents latent herpes in mice.
    Cremer KJ; Mackett M; Wohlenberg C; Notkins AL; Moss B
    Science; 1985 May; 228(4700):737-40. PubMed ID: 2986288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of adjuvants on the efficacy of a recombinant herpes simplex virus glycoprotein vaccine.
    Sanchez-Pescador L; Burke RL; Ott G; Van Nest G
    J Immunol; 1988 Sep; 141(5):1720-7. PubMed ID: 2842401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetically engineered herpes simplex virus vaccines.
    Watson RJ; Enquist LW
    Prog Med Virol; 1985; 31():84-108. PubMed ID: 2982176
    [No Abstract]   [Full Text] [Related]  

  • 17. Restriction of latent herpes virus infection in rabbits immunized with subviral herpes simplex virus vaccine.
    Rajcáni J; Kutinová L; Vonka V
    Acta Virol; 1980 May; 24(3):183-93. PubMed ID: 6107035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccines for latent viruses.
    Pass F
    J Am Acad Dermatol; 1988 Jan; 18(1 Pt 2):224-6. PubMed ID: 2828442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection and serum antibody responses in guinea-pigs and mice immunized with HSV-1 antigen preparations obtained using different detergents.
    Ertürk M; Welch MJ; Phillpotts RJ; Jennings R
    Vaccine; 1989 Oct; 7(5):431-6. PubMed ID: 2554607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenovirus vectors as potential vaccines against herpes simplex virus.
    Johnson DC
    Rev Infect Dis; 1991; 13 Suppl 11():S912-6. PubMed ID: 1664127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.